TY - JOUR
T1 - Energy substrate metabolism and mitochondrial oxidative stress in cardiac ischemia/reperfusion injury
AU - Dambrova, Maija
AU - Zuurbier, Coert J.
AU - Borutaite, Vilmante
AU - Liepinsh, Edgars
AU - Makrecka-Kuka, Marina
N1 - Funding Information:
This article is based upon work from COST Action EU‐CARDIOPROTECTION CA16225 supported by COST ( European Cooperation in Science and Technology ). C.J.Z. was supported by a grant from European Foundation of the Study of Diabetes and from Boehringer –Ingelheim to investigate the cardiac working mechanism of empagliflozin. V.B. received funding from the European Social Fund (project No 09.3.3-LMT-K-712-01-0131) under grant agreement with the Research Council of Lithuania . E.L. research is supported by funding from the Latvian Council of Science , project TRILYSOX, grant No. LZP-2018/1–0082.
Publisher Copyright:
© 2021 The Author(s)
PY - 2021/3/1
Y1 - 2021/3/1
N2 - The heart is the most metabolically flexible organ with respect to the use of substrates available in different states of energy metabolism. Cardiac mitochondria sense substrate availability and ensure the efficiency of oxidative phosphorylation and heart function. Mitochondria also play a critical role in cardiac ischemia/reperfusion injury, during which they are directly involved in ROS-producing pathophysiological mechanisms. This review explores the mechanisms of ROS production within the energy metabolism pathways and focuses on the impact of different substrates. We describe the main metabolites accumulating during ischemia in the glucose, fatty acid, and Krebs cycle pathways. Hyperglycemia, often present in the acute stress condition of ischemia/reperfusion, increases cytosolic ROS concentrations through the activation of NADPH oxidase 2 and increases mitochondrial ROS through the metabolic overloading and decreased binding of hexokinase II to mitochondria. Fatty acid-linked ROS production is related to the increased fatty acid flux and corresponding accumulation of long-chain acylcarnitines. Succinate that accumulates during anoxia/ischemia is suggested to be the main source of ROS, and the role of itaconate as an inhibitor of succinate dehydrogenase is emerging. We discuss the strategies to modulate and counteract the accumulation of substrates that yield ROS and the therapeutic implications of this concept.
AB - The heart is the most metabolically flexible organ with respect to the use of substrates available in different states of energy metabolism. Cardiac mitochondria sense substrate availability and ensure the efficiency of oxidative phosphorylation and heart function. Mitochondria also play a critical role in cardiac ischemia/reperfusion injury, during which they are directly involved in ROS-producing pathophysiological mechanisms. This review explores the mechanisms of ROS production within the energy metabolism pathways and focuses on the impact of different substrates. We describe the main metabolites accumulating during ischemia in the glucose, fatty acid, and Krebs cycle pathways. Hyperglycemia, often present in the acute stress condition of ischemia/reperfusion, increases cytosolic ROS concentrations through the activation of NADPH oxidase 2 and increases mitochondrial ROS through the metabolic overloading and decreased binding of hexokinase II to mitochondria. Fatty acid-linked ROS production is related to the increased fatty acid flux and corresponding accumulation of long-chain acylcarnitines. Succinate that accumulates during anoxia/ischemia is suggested to be the main source of ROS, and the role of itaconate as an inhibitor of succinate dehydrogenase is emerging. We discuss the strategies to modulate and counteract the accumulation of substrates that yield ROS and the therapeutic implications of this concept.
KW - Cardiac injury
KW - Energy metabolism
KW - Ischemia/reperfusion
KW - Long-chain acylcarnitines
KW - Mitochondria
KW - Reactive oxygen species
KW - Succinate
UR - http://www.scopus.com/inward/record.url?scp=85099831461&partnerID=8YFLogxK
U2 - 10.1016/j.freeradbiomed.2021.01.036
DO - 10.1016/j.freeradbiomed.2021.01.036
M3 - Article
C2 - 33484825
AN - SCOPUS:85099831461
SN - 0891-5849
VL - 165
SP - 24
EP - 37
JO - Free Radical Biology and Medicine
JF - Free Radical Biology and Medicine
ER -